SCYNEXIS (NASDAQ:SCYX – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13, Zacks reports. The business had revenue of $0.98 million during the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.
SCYNEXIS Stock Down 5.9 %
SCYNEXIS stock opened at $0.86 on Friday. SCYNEXIS has a 52 week low of $0.82 and a 52 week high of $3.07. The company has a market capitalization of $32.57 million, a price-to-earnings ratio of -1.16 and a beta of 1.67. The stock has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.26.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a report on Thursday.
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
See Also
- Five stocks we like better than SCYNEXIS
- Growth Stocks: What They Are, Examples and How to Invest
- Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus
- NYSE Stocks Give Investors a Variety of Quality Options
- Joby and Archer Lead the Charge in 2025’s Urban Air Revolution
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Undervalued Stocks You Can Buy at a Discount Now
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
